A heart surgeon just told patients to track a different number than “bad cholesterol,” and it could change who takes statins and when.
Story Snapshot
- Apolipoprotein B counts artery-clogging particles; low-density lipoprotein cholesterol measures cargo, not count.
- Guidelines recognize apolipoprotein B as a risk “enhancer,” not a universal test for everyone.
- Jeremy London, a cardiovascular surgeon, urges lifestyle first, then meds if apolipoprotein B stays high.
- Statins still lower events in higher-risk groups; the debate is about targeting, not tossing meds.
ApoB vs LDL-C: The Number That Counts Particles, Not Just Cholesterol
Jeremy London argues that apolipoprotein B points to risk because it tallies the number of atherogenic particles that can enter artery walls. Low-density lipoprotein cholesterol, the usual “bad cholesterol,” measures how much cholesterol rides inside those particles, not how many are in circulation. When those numbers disagree, apolipoprotein B often tracks risk better, especially in people with high triglycerides or insulin resistance. That simple shift—counting particles—reshapes who may need treatment, and how soon.
Professional guidance supports using apolipoprotein B to refine decisions, but stops short of replacing low-density lipoprotein cholesterol. The 2018 American Heart Association and American College of Cardiology guideline lists apolipoprotein B at or above 130 milligrams per deciliter as a risk-enhancing factor, particularly when triglycerides run high. That language leaves room for judgment. It helps flag patients who might benefit from statins when standard scores feel borderline.
What London Recommends: Sequence Lifestyle, Then Add Medicine If Needed
London lays out a simple order: fix lifestyle for three to six months, then use medication if apolipoprotein B stays high or if overall risk is high from the start. He reviews statins, ezetimibe, proprotein convertase subtilisin or kexin type 9 inhibitors, and bempedoic acid as tools, not ideologies. He calls statins effective with strong outcome data, which matches large trials and guideline positions for higher-risk patients. The focus is precision: treat the right people, aim at particle burden, and stay consistent.
Guidelines align with parts of that plan. They put lifestyle at the foundation and layer statins when risk crosses clear lines. They also endorse clinician-patient talks that weigh additional markers like apolipoprotein B and lipoprotein(a). That shared decision process matters because people differ. Some have normal low-density lipoprotein cholesterol but carry many small particles. Others have diabetes or kidney disease that raises their absolute risk even when standard labs look “okay”.
Targets, Thresholds, And Where Professional Guidance Draws The Line
London cites apolipoprotein B targets by risk tier, pushing lower numbers for higher risk. A recent scientific review describes similar ranges used by some expert groups, while the 2018 guideline highlights the 130 milligrams per deciliter level as a risk enhancer rather than a universal treatment target. That split explains the heat online. Clinicians debate thresholds; patients hear mixed messages. The practical takeaway is simple: use apolipoprotein B to sharpen risk calls, not to bypass proven therapy where events can be prevented.
One caveat belongs in plain view. London’s video is educational content, not a formal guideline. The core ideas align with established guidance on lifestyle, shared decisions, and statins for higher-risk groups, but not every numeric target has a single governing rule for all patients. That is why a conversation with a clinician who knows your full risk profile still beats a one-size chart.
How To Act On This: A Commonsense Playbook
Order the test if you and your clinician face a gray-zone choice. If apolipoprotein B is high, clean up the inputs fast: lose visceral fat, cut refined carbs and added sugar, eat more fiber, replace saturated fats with unsaturated fats, and move daily. Retest in three months. If apolipoprotein B stays high or your overall risk is high, start a statin and add other drugs as needed to hit a sensible target. That plan honors personal responsibility and uses medicine where it prevents harm.
Do not let social media noise push you into all-or-nothing thinking. The evidence shows statins reduce heart attacks and strokes in the right patients. Apolipoprotein B helps find those patients sooner and treats the problem—too many atherogenic particles—more directly. That is not hype. That is better triage with the tools we already have. Ask for the number that counts, and use it to make a clear, grown-up decision with your doctor.
Sources:
acc.org, ahajournals.org, linkedin.com
